title: Fluoxetine reduces murine graft-versus-host disease by induction of T cell immunosuppression.
abstract: Serotonin reuptake inhibitors (SRIs) are widely used drugs in the treatment of depression and anxiety disorders. Although SRIs are generally regarded as safe drugs with relatively few side effects, literature suggests that high concentrations of SRIs may alter immune function. We investigated whether high-dose treatment with fluoxetine was able to suppress acute graft-versus-host disease (GvHD) in a MHC-matched, minor histocompatibility antigen mismatched murine bone marrow transplantation model. We found that high doses fluoxetine induce a significant reduction of clinical symptoms and increase survival of these animals. The amelioration of clinical GvHD was accompanied by a reduced expansion of alloreactive T cells. We further analyzed the direct in vitro effect of six SRIs on the viability and proliferation of human T cells and found an anti-proliferative and pro-apoptotic effect that was significantly larger in activated than in resting T cells. We discuss these results in the light of potential future exploration of SRIs as a novel class of T cell immunosuppressive drugs.
authors: Laboratory of Pharmaceutical Biotechnology, Faculty of Pharmaceutical Sciences, University of Ghent, Harelbekestraat 72, 9000 Ghent, Belgium.
authors: Veerle
authors: V
authors: Gobin
authors: Katleen
authors: K
authors: Van Steendam
authors: Sabine
authors: S
authors: Fevery
authors: Kelly
authors: K
authors: Tilleman
authors: An D
authors: AD
authors: Billiau
authors: Damiaan
authors: D
authors: Denys
authors: Dieter L
authors: DL
authors: Deforce
mesh_terms: D000818:Animals; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D005260:Female; D005473:Fluoxetine / Q000494:pharmacology / Q000627:therapeutic use*; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology; D051379:Mice; D008806:Mice, Inbred AKR; D008809:Mice, Inbred C3H; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology
chemical_list: D005473:Fluoxetine; D007166:Immunosuppressive Agents; D017367:Selective Serotonin Reuptake Inhibitors
references: Basic Clin Pharmacol Toxicol. 2006 Aug;99(2):91-5
references: 16918708
references: Neuroimmunomodulation. 2011;18(2):117-22
references: 21088435
references: Respir Res. 2007 May 03;8:35
references: 17477857
references: Leukemia. 2007 Jul;21(7):1451-9
references: 17508005
references: Tissue Antigens. 2003 Jun;61(6):415-24
references: 12823765
references: Psychopharmacology (Berl). 2002 Apr;161(1):95-9
references: 11967636
references: Pharmacol Biochem Behav. 1998 Jan;59(1):151-7
references: 9443550
references: Blood. 1992 Dec 15;80(12):2964-8
references: 1467511
references: Neuropsychopharmacology. 1999 Apr;20(4):370-9
references: 10088138
references: Neuroimmunomodulation. 2000;8(4):179-87
references: 11251392
references: Neuropsychopharmacology. 2004 Jul;29(7):1321-30
references: 15085085
references: Eur Neuropsychopharmacol. 2003 Jan;13(1):53-6
references: 12480123
references: J Clin Psychopharmacol. 2001 Apr;21(2):199-206
references: 11270917
references: Immunopharmacol Immunotoxicol. 1994 May;16(2):165-78
references: 8077605
references: Leuk Lymphoma. 2010 Mar;51(3):523-39
references: 20141432
references: Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90
references: 16388933
references: Eur J Pharmacol. 1999 May 7;372(1):65-73
references: 10374716
references: Int J Immunopharmacol. 1994 Jul;16(7):561-7
references: 7928004
references: Neuroimmunomodulation. 2012;19(4):201-8
references: 22441536
references: Int J Immunopharmacol. 1997 Nov-Dec;19(11-12):645-54
references: 9669204
references: Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58
references: 9537821
references: Transplantation. 2001 Jan 27;71(2):292-9
references: 11213076
references: Pharmacol Rep. 2012;64(3):714-22
references: 22814024
references: Cytometry A. 2011 Feb;79(2):95-101
references: 21265003
references: Int Immunopharmacol. 2008 Apr;8(4):526-33
references: 18328443
references: Prog Neuropsychopharmacol Biol Psychiatry. 2003 Feb;27(1):85-102
references: 12551730
references: Int Immunopharmacol. 2005 Mar;5(3):609-18
references: 15683856
references: J Neuroimmunol. 2008 May 30;196(1-2):173-80
references: 18462811
references: Immunopharmacology. 1996 Aug;34(1):27-37
references: 8880223
references: Blood. 2002 Sep 1;100(5):1894-902
references: 12176914
references: Eur Neuropsychopharmacol. 2007 Dec;17(12):774-80
references: 17499975
references: J Chromatogr B Biomed Sci Appl. 1997 Dec 19;704(1-2):259-63
references: 9518159
references: Arthritis Rheum. 2010 Mar;62(3):683-93
references: 20131240
references: Am J Psychiatry. 1991 Jul;148(7):949-50
references: 1647143
references: Blood. 2002 Apr 1;99(7):2545-53
references: 11895792
references: Cell Signal. 1998 Nov;10(10):721-6
references: 9884023
references: Int J Neuropsychopharmacol. 2009 May;12(4):525-36
references: 18922202
references: Transplantation. 2000 Jul 27;70(2):348-53
references: 10933162
references: J Clin Psychiatry. 1998;59 Suppl 15:42-8
references: 9786310
references: Psychopharmacology (Berl). 2002 Dec;164(4):432
references: 12457275
references: Eur J Immunol. 1995 Feb;25(2):364-8
references: 7875197
references: J Immunol. 1995 May 15;154(10):5542-54
references: 7730653